The stock of Gilead Sciences Inc. (NASDAQ:GILD) last traded at $83.62, unchanged from the previous session.
Data from the available sources indicates that Gilead Sciences Inc. (NASDAQ:GILD) is covered by 30 analysts. The consensus rating among analysts is ‘Overweight’. GILD stock price is now 19.14% away from the 50-day moving average and 30.87% away from the 200-day moving average. The market capitalization of the company currently stands at $104.88B.
In total, 17 analysts have assigned it a hold rating, and 13 have given it a buy rating.
With the price target enhanced from $60 to $76, Barclays Upgraded its rating from Underweight to Equal Weight for Gilead Sciences Inc. (NASDAQ: GILD). On October 28, 2022, Truist Upgraded its previous ‘Hold’ rating to ‘Buy’ on the stock increasing its target price from $76 to quote $91, while ‘Piper Sandler’ rates the stock as ‘Overweight’.
In other news, Wilfong Diane E., SVP, Controller & CAO sold 6,416 shares of the company’s stock on Nov 09. The stock was sold for $535,736 at an average price of $83.50. Upon completion of the transaction, the SVP, Controller & CAO now directly owns 28,333 shares in the company, valued at $2.37 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 01, SVP, Controller & CAO Wilfong Diane E. sold 16,255 shares of the business’s stock. A total of $1,288,209 was realized by selling the stock at an average price of $79.25. This leaves the insider owning 28,333 shares of the company worth $2.37 million. Insiders disposed of 142,209 shares of company stock worth roughly $11.89 million over the past 1 year. A total of 0.09% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in GILD stock. A new stake in Gilead Sciences Inc. shares was purchased by FARMER STEVEN PATRICK during the first quarter worth $109,518,000. ANTIPODES PARTNERS LTD invested $89,206,000 in shares of GILD during the first quarter. In the first quarter, POLARIS CAPITAL MANAGEMENT, LLC acquired a new stake in Gilead Sciences Inc. valued at approximately $54,504,000. POINT72 ASSET MANAGEMENT, L.P. acquired a new stake in GILD for approximately $47,070,000. SOFINNOVA INVESTMENTS, INC. purchased a new stake in GILD valued at around $40,338,000 in the second quarter. In total, there are 2,203 active investors with 83.00% ownership of the company’s stock.
With an opening price of $83.63 on Friday morning, Gilead Sciences Inc. (NASDAQ: GILD) set off the trading day. During the past 12 months, Gilead Sciences Inc. has had a low of $57.17 and a high of $84.14. As of last week, the company has a debt-to-equity ratio of 1.20, a current ratio of 1.30, and a quick ratio of 1.20. The fifty day moving average price for GILD is $70.55 and a two-hundred day moving average price translates $63.98 for the stock.
The latest earnings results from Gilead Sciences Inc. (NASDAQ: GILD) was released for Jun, 2022. According to the Drug Manufacturers – General Company, earnings per share came in at $1.9, beating analysts’ expectations of $1.43 by 0.47. This compares to $2.05 EPS in the same period last year. The net profit margin was 12.30% and return on equity was 16.20% for GILD. The company reported revenue of $7.04 billion for the quarter, compared to $7.42 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -5.11 percent. For the current quarter, analysts expect GILD to generate $6.35B in revenue.
Moreover, the firm recently paid out its quarterly dividend on 12/29/2022. Investors who held shares on 12/15/2022 were paid a $0.73 dividend. On an annualized basis, this represents a $2.92 dividend and a 3.49% percent yield. There was an ex-dividend date of 12/14/2022 for this dividend. In terms of dividend payout ratio, GILD is presently at 109.20%.
Gilead Sciences Inc.(GILD) Company Profile
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.